Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays

British Journal of Pharmacology

Volumn 171, Issue 22, 2014, Pages 5127-5138

  Gilchrist, A ^a,e   Gauntner, T D ^b   Fazzini, A ^c,f   Alley, K M ^b   Pyen, D S ^a   Ahn, J ^a   Ha, S J ^b   Willett, A ^a,g   Sansom, S E ^b   Yarfi, J L ^d   Bachovchin, K A ^d   Mazzoni, M R ^c   Merritt, J R ^d  

^a Chicago College of Pharmacy   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d KEAN UNIVERSITY   (United States)

^e MIDWESTERN UNIVERSITY   (United States)

^f ISI Marconi   (Italy)

^g Henry Ford Museum   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; AZD 4818; BETA ARRESTIN; CCX 354; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CP 481715; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MLN 3897; PS 899877; UNCLASSIFIED DRUG; AZD-4818; CARBANILAMIDE DERIVATIVE; CCR1 PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; QUINOXALINE-2-CARBOXYLIC ACID (4-CARBAMOYL-1-(3-FLUOROBENZYL)-2,7-DIHYDROXY-7-METHYLOCTYL)AMIDE; RETINA S ANTIGEN; SPIRO COMPOUND;

ARTICLE; CELL MIGRATION; CELLULAR DISTRIBUTION; CHEMOTAXIS ASSAY; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; MULTIPLE MYELOMA CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMOTAXIS; CHO CELL LINE; CRICETULUS; HEK293 CELL LINE; METABOLISM; MULTIPLE MYELOMA; RADIOASSAY; TUMOR CELL LINE;

ANIMALS; ARRESTINS; CELL LINE, TUMOR; CHEMOKINE CCL3; CHEMOTAXIS; CHO CELLS; CRICETULUS; HEK293 CELLS; HUMANS; MULTIPLE MYELOMA; PHENYLUREA COMPOUNDS; PIPERIDINES; QUINOXALINES; RADIOLIGAND ASSAY; RECEPTORS, CCR1; SPIRO COMPOUNDS;

EID: 84907183530     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12835     Document Type: Article

References (54)

1. Ajram L, Begg M, Slack R, Cryan J, Hall D, Hodgson S et al. (2014). Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists. Eur J Pharmacol 729C: 75-85.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, Locati M (2008). Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharmacol Sci 29: 280-286.
4. An S, Bleu T, Zheng Y (1999). Transduction of intracellular calcium signals through G protein-mediated activation of phospholipase C by recombinant sphingosine 1-phosphate receptors. Mol Pharmacol 55: 787-794.
5. Anders H, Vielhauer V, Frink M, Linde Y, Cohen C, Blattner S et al. (2002). A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 109: 251-259.
6. Badr G, Lefevre E, Mohany M (2011). Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS ONE 6: e23741.
7. Carson KG, Harriman GC (2004) CCR1 Antagonists for The Treatment of I.A. Demyelinating Inflammatory Disease, PCT. Millennium Pharmaceuticals, Inc: Patent no. WO/2004/043965.
8. Choi S, Cruz J, Craig F, Chung H, Devlin R, Roodman G et al. (2000). Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96: 671-675.
9. Christopoulos A, Kenakin T (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374.
10. Cooper M, Elkins B, Gibson S, Gu E, Hassall I, Hemmerling M et al. (2009). A process for the preparation of intermediates and their use in the the synthesis of spiropiperidine compounds. Patent no. WO/2009/011653.
11. Dairaghi D, Zhang P, Wang Y, Seitz L, Johnson D, Miao S et al. (2011). Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clin Pharmacol Ther 89: 726-734.
12. Dairaghi D, Oyajobi B, Gupta A, McCluskey B, Miao S, Powers J et al. (2012). CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 120: 1449-1457.
13. DeWire S, Ahn S, Lefkowitz R, Shenoy S (2007). Beta-arrestins and cell signaling. Annu Rev Physiol 69: 483-510.
14. Gardner D, Santella JB Jr, Duncia J, Carter P, Dhar T, Wu H et al. (2013). The discovery of BMS-457, a potent and selective CCR1 antagonist. Bioorg Med Chem Lett 23: 3833-3840.
15. Gilchrist A, Mazzoni M, Dineen B, Dice A, Linden J, Dunwiddie T et al. (1998). Antagonists of the receptor-G protein interface block Gi-coupled signal transduction. J Biol Chem 273: 14912-14919.
16. Gilliland C, Salanga C, Kawamura T, Trejo J, Handel T (2013). The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization. J Biol Chem 288: 32194-32210.
17. Gladue R, Tylaska L, Brissette W, Lira P, Kath J, Poss C et al. (2003). CP-481 715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem 278: 40473-40480.
18. Gladue R, Brown M, Zwillich S (2010). CCR1 antagonists: what have we learned from clinical trials. Curr Top Med Chem 10: 1268-1277.
19. Hansson J, Eriksson T, Mensonides-Harsema M, Mo J (2008). Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (COPD) and asthma. : AstraZeneca. Patent no. WO/2008/103126.
20. Hemmerling M, Ivanova S, Mensonides-Harsema M, Schulz H (2009). Spiropiperidine compounds, a process of their preparation, pharmaceutical compositions containing them, and their use in the treatment of airway diseases, inflammatory diseases, COPD or asthma.: AstraZeneca. Patent no. WO/2009/011655.
21. Hesselgesser J, Ng H, Liang M, Zheng W, May K, Bauman J et al. (1998). Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 273: 15687-15692.
22. Horuk R (2005). BX471: a CCR1 antagonist with anti-inflammatory activity in man. Mini Rev Med Chem 5: 791-804.
23. Hossain N, Mensonides-Harsema M, Cooper M, Eriksson T, Ivanova S, Bergström L (2014). Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists. Bioorg Med Chem Lett 24: 108-112.
24. Karash A, Gilchrist A (2011). Therapeutic potential of CCR1 antagonists for multiple myeloma. Future Med Chem 3: 1889-1908.
25. Kenakin T (1996). The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 48: 413-463.
26. Kenakin T, Jenkinson S, Watson C (2006). Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319: 710-723.
27. Kerstjens H, Bjermer L, Eriksson L, Dahlström K, Vestbo J (2010). Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. Respir Med 104: 1297-1303.
28. Lentzsch S, Gries M, Janz M, Bargou R, Dörken B, Mapara M (2003). Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101: 3568-3573.
29. Lentzsch S, Anderson G, Cuiling L, Horuk R, Mapara M, Ghobrial I et al. (2005). ASH annual meeting abstracts. Blood 106: Abstract 3383.
30. Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S et al. (2007). Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 46: 226-238.
31. Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S et al. (2003). Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101: 4998-5006.
32. May L, Leach K, Sexton P, Christopoulos A (2007). Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51.
33. Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K et al. (2006). Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 23: 291-300.
34. Merritt J, Liu J, Quadros E, Morris M, Liu R, Zhang R et al. (2009). Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists. J Med Chem 52: 1295-1301.
35. Merritt J, James R, Paradkar V, Zhang C, Liu R, Liu J et al. (2010). Novel pyrrolidine heterocycles as CCR1 antagonists. Bioorg Med Chem Lett 20: 5477-5479.
36. Neel N, Schutyser E, Sai J, Fan G, Richmond A (2005). Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev 16: 637-658.
37. Neote K, DiGregorio D, Mak J, Horuk R, Schall T (1993). Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 72: 415-425.
38. Norman P (2009). AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653. Expert Opin Ther Pat 19: 1629-1633.
39. Oba Y, Lee J, Ehrlich L, Chung H, Jelinek D, Callander N et al. (2005). MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 33: 272-278.
40. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-D1106.
41. Pease J, Horuk R (2009). Chemokine receptor antagonists: part 1. Expert Opin Ther Pat 19: 39-58.
42. Pennell A, Aggen J, Wright J, Sen S, McMaster B, Dairaghi D et al. (2010). Substituted piperazines: Chemocentryx, Inc. Patent no. US2004/0162282.
43. Pennell A, Aggen J, Sen S, Chen W, Xu Y, Sullivan E et al. (2013). 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists. Bioorg Med Chem Lett 23: 1228-1231.
44. Raab M, Podar K, Breitkreutz I, Richardson P, Anderson K (2009). Multiple myeloma. Lancet 374: 324-339.
45. Rajagopal S, Bassoni D, Campbell J, Gerard N, Gerard C, Wehrman T (2013). Biased agonism as a mechanism for differential signaling by chemokine receptors. J Biol Chem 288: 35039-35048.
46. Robbins A, Horlick R (1998). Macrophage scavenger receptor confers an adherent phenotype to cells in culture. Biotechniques 25: 240-244.
47. Roussou M, Tasidou A, Dimopoulos M, Kastritis E, Migkou M, Christoulas D et al. (2009). Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 23: 2177-2181.
48. Sezer O (2009). Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist 14: 276-283.
49. Sun Y, Cheng Z, Ma L, Pei G (2002). Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem 277: 49212-49219.
50. Trentin L, Miorin M, Facco M, Baesso I, Carraro S, Cabrelle A et al. (2007). Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol 138: 594-602.
51. Tsou C, Gladue R, Carroll L, Paradis T, Boyd J, Nelson R et al. (1998). Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor. J Exp Med 188: 603-608.
52. Vaidehi N, Schlyer S, Trabanino R, Floriano W, Abrol R, Sharma S et al. (2006). Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 281: 27613-27620.
53. Vallet S, Anderson K (2011). CCR1 as a target for multiple myeloma. Expert Opin Ther Targets 15: 1037-1047.
54. Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S et al. (2007). MLN-3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 110: 3744-3752.